HSA Singapore (Health Sciences Authority): Therapeutic Products, Devices and Health Supplements
A practical guide to product categories, HSA guidance and the human decisions behind registration, supply and lifecycle management in Singapore.

On this page · 12 sections
- 1What HSA Singapore means for product teams
- 2Separate law, HSA guidance and company controls
- 3Map Singapore products and activities before choosing a route
- 4Therapeutic products: registration and dealer licensing
- 5Medical devices: evaluation route, risk class and grouping
- 6Health supplements: import, manufacture, sale and claims
- 7Overseas GMP evidence and imported vaccine lot information
- 8Build a product-to-decision evidence model
- 9Connect records and recover from handoff failures
- 10Worked cases: different products, different next actions
- 11Keep lifecycle signals connected to product decisions
- 12Review checklist: catch category and evidence failures
How does HSA (Singapore) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What HSA Singapore means for product teams
HSA Singapore means the Health Sciences Authority in Singapore, abbreviated HSA. This article covers therapeutic products, medical devices and health supplements—not HSA’s entire remit. These categories need separate treatment; a company’s records should preserve the category associated with each activity and decision.
In practice this means three different pathways. For therapeutic products, HSA's therapeutic-products overview requires product registration and a dealer's licence before import, manufacture or wholesale. For medical devices, HSA's registration guides entry uses an evaluation route tied to risk class, with devices optionally grouped under one registration. For health supplements, HSA's health-supplements overview covers import, sale and manufacture regulations and permissible claims, and separately links to voluntary notification of complementary health products for products that are eligible—not every supplement qualifies. The scope matrix and category sections that follow map each pathway to the records a company needs to keep them distinct.
The following are practical distinctions for organising work, not universal legal definitions or interchangeable forms of approval. A record’s legal effect depends on the applicable product category and instrument.
| Term | Operational meaning |
|---|---|
| Authority | HSA itself, rather than a company-held record. |
| Product-registration record | Tracks a product’s registration status and associated decision. |
| Business-activity licence record | Tracks a licence associated with an entity and specified activities. |
| Notification reference | Identifies a notification; keep its purpose and status explicit. |
| Internal product-release decision | Records the company’s accountable decision to release identified product or batches. |
In controlled-record practice, submission means sending information; acknowledgement records receipt; a regulatory decision records the authority’s determination; and internal release records the company’s disposition. These are separate events, not successive labels for the same approval.
People remain responsible for interpretation, approval and batch release. An electronic release record can document that decision, but the existence of a record or reference is not itself a release decision.
02Separate law, HSA guidance and company controls
Use an authority map to separate legal authority from explanation and implementation. For legal scope, check the current binding instrument applicable to the Singapore product category and activity; do not treat an HSA guidance-page summary as statutory text.
| Authority-map entry | Review purpose |
|---|---|
| Applicable binding instrument | Identify the legal provision and its product and activity scope. |
| HSA guidance | Identify the category-specific explanation without relabelling it as legislation. |
| Company procedure | Identify the internal control, its owner and approval basis. |
| Software-supported task | Identify the intended record-handling task and the human review or approval retained. |
For each source, record its title, jurisdiction, product category, activity, exact passage, source type and the decision it supports. Preserve conditional wording, including may: an option or qualification should not become a universal obligation in a checklist. This distinction also helps keep broad GxP terminology from replacing a product-specific scope assessment.
Treat foreign authorisations as separately identified evidence. Record the issuing jurisdiction, product identity and decision scope. Leave any effect on a Singapore pathway to a category-specific assessment rather than assuming equivalence, reliance eligibility or transferred permission.
Label company-designed review gates explicitly. An internal control may be stricter or more detailed than the guidance it supports without becoming an HSA instruction. For example, a chosen audit trail review workflow belongs under company procedure unless a separate authority supports attributing it to HSA. Keep the rationale and approver visible.
03Map Singapore products and activities before choosing a route
Start with a Singapore-specific scoping matrix, rather than a single registration task for every product. The proposed company matrix below separates category questions from planned activities. Keep other destination markets in separate assessments; a category conclusion recorded for one market should not silently populate another.
| Jurisdiction | Product category | Proposed activity and inputs | Classification status | Decision to resolve | Evidence owner | Unresolved question |
|---|---|---|---|---|---|---|
| Singapore | Therapeutic products | Import, manufacture or wholesale; identify each proposed activity | Record working state | Category and activity scope | Regulatory lead | Which activities will this business perform? |
| Singapore | Medical devices | Proposed supply; intended purpose and product configuration | Record working state | Product boundary under review | Regulatory and technical leads | Which configuration does the assessment cover? |
| Singapore | Health supplements | Import, manufacture or sale; formulation, presentation and proposed claims | Record working state | Category assessment for the proposed product | Regulatory and formulation leads | Are the proposed claims and presentation settled? |
These are assessment inputs, not self-executing legal classification tests. The owner roles are illustrative company assignments. Use distinct working states: confirmed category for a completed company assessment, provisional category for a working conclusion with open assumptions, and unresolved category where no conclusion is recorded. Capture the assessor, product version, rationale and uncertainty to resolve before selecting the next action.
Illustrative company review sequence
This is an internal coordination model, not an HSA-mandated procedure:
- Identify the product and version; use consistent identifiers, as in production context tagging.
- Record the category assessment, then map proposed business activities without treating them as classification proof.
- Review supporting evidence and open questions; have the designated human reviewer record the next-action decision.
- Connect lifecycle changes to that decision so affected assumptions can be reconsidered. An audit trail review workflow can help structure review of record changes.
- Identify productCapture intended purpose, presentation and proposed Singapore activities.
- Resolve categoryRecord the assessment owner, rationale and unresolved questions.
- Map activitySeparate product, legal-entity and site-related review work.
- Plan evidenceConnect category-specific questions to documents and responsible owners.
- Review packageCheck identities, versions and exceptions before controlled handoff.
- Record decisionsDistinguish external decisions from internal approval and release.
- Manage lifecycleLink changes and safety signals to documented follow-up.
05Medical devices: evaluation route, risk class and grouping
For medical devices in Singapore, HSA’s registration guides entry directs readers to use the relevant guide after determining the evaluation route and risk class. The preparation sequence is therefore to establish those decisions before using the corresponding registration guide—not to choose a convenient document checklist and work backwards.
For medical devices in Singapore, HSA’s grouping entry discusses grouping multiple devices for product registration. As an internal review practice, keep the grouping assessment separate from the risk-class and evaluation-route assessments. Record each conclusion and its basis so that a proposed group does not silently become the justification for another decision.
Define the devices under review
A practical assessment can use the following review inputs. These are suggested company controls, not HSA-mandated dossier fields:
- Intended purpose and the model identifiers included in the assessment.
- Configurations and accessories under review, with any uncertain boundaries identified.
- Proposed grouping rationale linked to the configurations it covers.
- Unresolved questions, the evidence needed to address them and a named review owner.
A commercial product-family name is not an adequate internal grouping rationale: it identifies a marketed range but does not explain the proposed regulatory grouping. A reviewer commonly compares the actual configurations and preserves the basis for accepting, rejecting or deferring the company’s proposal. Check the current HSA guidance for the applicable Singapore medical-device grouping criteria.
Preserve the decision trail
Use a decision log to keep the proposed route, supporting references, reviewer conclusions and outstanding evidence visible. If preparation draws on a 510(k) project, label that material as background and document the Singapore assessment separately. This keeps reused evidence distinguishable from the company’s current route proposal. Record what remains unresolved rather than treating submission readiness as a prediction of HSA acceptance, cost savings or processing outcomes for an individual application.
06Health supplements: import, manufacture, sale and claims
For health supplements in Singapore, HSA’s health-supplements overview directs readers to understand the regulations and permissible health claims before importing, selling or manufacturing them. Treat this guidance as the starting point for reviewing both the intended business activity and the product’s consumer-facing wording.
For health supplements in Singapore, HSA’s overview also links to voluntary notification of complementary health products and a list of notified complementary health products. These links provide navigation to the notification process and notified-products list; do not treat a listing as a product-registration decision or assume every supplement is eligible.
For a particular supplement, check the current HSA category guidance and notification-scheme scope before deciding which process applies. Record unresolved category or scope questions for review rather than filling the gap with a therapeutic-product or medical-device rule.
Keep product identity and claims together
A practical company review file connects the following inputs. This is an internal review structure, not a prescribed HSA dossier:
- Formulation and ingredient identities, tied to relevant supplier information.
- The label version and exact proposed consumer claims, with supporting material organised for claims substantiation.
- Sales-channel content, including the product-page wording under review, rather than only a broad marketing description.
- The reviewer’s conclusion, unresolved wording and the version to which the conclusion applies.
Reopen messaging review when needed
An unchanged formulation does not necessarily mean the internal claims assessment remains current. If a sales team changes a product-page headline while the ingredients and label stay unchanged, the new message can still warrant review. Compare the previous and proposed wording, identify the supporting rationale and route uncertainty to a named reviewer before publication. Keep the decision attached to the specific communication version. This is a risk-based company control, not a generic permitted-claims list or a predetermined legal classification of the new wording.
07Overseas GMP evidence and imported vaccine lot information
For overseas drug-product manufacturers seeking therapeutic-product registration in Singapore, HSA’s GMP conformity-assessment entry says an HSA Good Manufacturing Practice (GMP) conformity assessment may apply. This is conditional wording, not a statement that every overseas drug-product manufacturer undergoes the assessment.
For overseas drug-substance manufacturers supporting therapeutic-product registrations or variations in Singapore, HSA’s GMP evidence entry says evidence of GMP compliance will be needed. This guidance addresses drug-substance evidence separately from the drug-product conformity-assessment topic; the two entries should not become one undifferentiated GMP checklist.
For imported registered vaccines intended for supply in Singapore, HSA’s lot-release notification entry directs businesses to notify HSA of lot-release information before supply. That instruction concerns the specified vaccine import-and-supply activity, rather than overseas manufacturing evidence generally.
Review evidence against its intended use
As company practice, an evidence index commonly connects each quality document to its manufacturer role, site, product or substance, document version and assessment purpose. A general cGMP reference can support terminology, but document review is a separate task. An available file still needs human review of whether its identity and scope match the intended use.
- Identify whether the record concerns the drug-product manufacturer, the drug-substance manufacturer or an imported vaccine lot.
- Record the site and product or substance covered, alongside the document version and intended assessment purpose.
- Keep the reviewer’s suitability decision with the evidence, rather than treating file presence as acceptance.
- Use change control to flag manufacturer, site or document changes for reconsideration of the evidence’s intended use.
These are practical evidence-management controls, not additional HSA document requirements.
08Build a product-to-decision evidence model
A company-designed evidence model can connect product identity, regulatory work and review outcomes without treating every document as a separate case. The following entities are a proposed internal traceability design, not an HSA database schema or prescribed submission structure.
| Entity | Suggested record content |
|---|---|
| Product | Stable identifier, product category and identity details. |
| Activity | Product reference, intended regulatory activity, scope and responsible person. |
| Evidence | Document identifier, controlled version and location of the retained content. |
| Submission | Activity reference, package snapshot and references to submitted evidence versions. |
| Decision | Assessed version, outcome, decision_type, decision_owner, source_reference and open conditions. |
| LifecycleEvent | Affected product, evidence version, proposed change, baseline and review owner. |
Allow a Product to link to distinct Activity records rather than collapsing all work into a single status. Evidence versions can support multiple Submissions and Decisions; LifecycleEvent records can reference the affected Product and Evidence version. Preserve those relationships through stable identifiers and controlled document references, without copying the entire document into every record.
Keep an immutable reference to the retained submitted package while later working documents develop separately. Record exactly which version a reviewer assessed, the decision made and any unresolved condition. An audit trail can complement this model by retaining the history of record changes; it does not replace the submitted package.
Use decision_type and decision_owner to distinguish a regulatory decision from an internal quality or commercial decision. Connect source_reference to the supporting communication or record. A folder name or dashboard colour is not decision provenance, and an internal approval should not be relabelled as an authority’s decision.
For lifecycle changes, compare the proposed product or document state with the relevant baseline and assign a review owner. A recipe supersession log may support that comparison where formulation records change. Assess any external regulatory action separately against the applicable Singapore product-category guidance rather than encoding a universal change rule.
Product
Identifies the product and assessment scope.
- product_id
- target_market
- category_status
- intended_purpose
- label_version
Activity
Connects proposed operations to entities and sites.
- activity_id
- product_id
- activity_type
- legal_entity
- site_id
Evidence
Preserves document identity, provenance and version.
- evidence_id
- product_id
- document_type
- version_id
- source_reference
Submission
Identifies the package actually handed over.
- submission_id
- activity_id
- submitted_version
- submission_reference
- status
Decision
Records decision type and accountable ownership.
- decision_id
- related_record_id
- decision_type
- decision_owner
- decision_date
LifecycleEvent
Connects changes or signals to disposition.
- event_id
- product_id
- event_type
- affected_version
- disposition
09Connect records and recover from handoff failures
A practical integration boundary connects product-master data, controlled documents, quality events and submission tracking through stable identifiers and explicit ownership. Before transferring data, define the authoritative source for each field: product identity, manufacturer-site reference, document revision and submission status. Assign an owner to resolve conflicting values rather than letting the latest transfer overwrite them. These are company-designed data-integrity controls, not HSA submission instructions.
Consider an incoming evidence record linked to the wrong manufacturer site. Place that record in a review state and pause its use in the affected package. Retain the original payload, transfer reference and incorrect relationship so the reviewer can reconstruct the handoff. Have the designated owner correct the mapping under change control, then reassess dependent packages before continuing the company workflow. This is an illustrative recovery procedure, not an HSA-prescribed process.
Use explicit exception states: duplicate identifier, transfer failed and acknowledgement pending. Assign product-data conflicts to the master-data owner, document failures to document control and acknowledgement checks to the submission coordinator. An exception-based review queue can organise this proposed workflow. Reconcile the receiving record against the intended content; successful transmission alone does not establish a complete package or an accepted submission.
Use software to organise records and route tasks within the company-designed process. Keep regulatory interpretation, evidence acceptance and release with responsible humans. This proposed support model does not imply direct HSA connectivity, automated approval or compliance certification.
10Worked cases: different products, different next actions
These hypothetical cases illustrate company review practices, not additional regulatory requirements. Each uses a distinct record-level unit of review.
Therapeutic product: separate manufacturer roles
Assume the therapeutic-product category is confirmed, the destination is Singapore, and an importer is preparing a registration package involving overseas drug-product and drug-substance manufacturers. The unit of review is a product–manufacturer-role relationship. Compare each role with the quality topics covered above rather than accepting a generic manufacturer evidence folder. Assign the relevant manufacturer’s quality contact as evidence owner; record unresolved applicability questions against the relationship.
Next action: the importer’s regulatory lead requests role-specific clarification. Evidence record: a manufacturer-role assessment linking the product, site, evidence version, owner and open question.
Medical device: assess the proposed grouping
Assume a proposed Singapore registration includes related model configurations, but grouping remains unresolved. The unit of review is a proposed device grouping. Compare configuration differences, preserve the proposed rationale and refer the decision to the relevant current HSA device-registration guidance.
Next action: the device regulatory specialist evaluates the proposal. Evidence record: an internal grouping assessment with a configuration comparison and unresolved questions—not a prediction of HSA acceptance.
Health supplement: review revised wording
Assume a Singapore seller proposes revised consumer claims without changing the formulation. The unit of review is a label-and-claims version. Compare the proposed wording with the reviewed baseline through change control, identify the unresolved claim question and withhold internal approval of that wording until the reviewer resolves it. This example alone does not establish a new legal category.
Next action: the seller’s designated claims reviewer resolves the question. Evidence record: the wording comparison, review rationale and recorded approval or rejection.
11Keep lifecycle signals connected to product decisions
For therapeutic products in Singapore, HSA’s Post-market surveillance, safety monitoring and advertisement entry directs readers to requirements concerning those subjects.
As an internal lifecycle-management practice supporting post-market surveillance, link each complaint, safety concern, advertising question or product change to the affected product version and an assigned reviewer. Separate initial triage from the decision about any external action: the reviewer assesses that question using the applicable current guidance for the product category. This record structure is a company control, not a reporting threshold.
A practical company closure rule is to close the internal event only when its disposition, supporting evidence and follow-up owner are recorded. Use the evidence model described above to connect the event and decision records, rather than introducing a separate status vocabulary.
12Review checklist: catch category and evidence failures
Use these proposed controls to test the distinctions covered above before closing a review.
| Failure | Review control |
|---|---|
| Unresolved category treated as final | Keep classification open; assign an owner to resolve the rationale. |
| Product registration confused with business licensing | Check separate product and activity records against their source references. |
| Commercial device-family name replaces grouping assessment | Review the documented grouping rationale, not the catalogue label. |
| Supplement wording changes outside claims review | Compare approved and proposed wording through change control. |
| Manufacturer role mismatched | Check the evidence identity against the recorded manufacturer role. |
| Wrong site linked | Match site name and address to the referenced evidence. |
| Stale document version | Compare the submission copy with the current approved version. |
| Submission status interpreted as a decision | Review the underlying decision reference rather than a workflow label. |
This is a review aid, not a certificate of compliance or a substitute for category-specific regulatory assessment.
- Regulatory: confirm product and Singapore jurisdiction; check current source scope.
- Supply chain: identify the activity and accountable owner.
- Quality: reconcile evidence identities and versions; review unresolved exceptions using exception-based review.
- Commercial: confirm that intended wording matches the reviewed claims.
- Cross-functional team: confirm the relevant human decision and assign lifecycle ownership within the company’s operating model.
Frequently asked questions
Q.How should a team handle a product whose intended category is still uncertain?+
Treat classification as an unresolved decision rather than choosing the most convenient submission pathway. Prepare a product profile covering composition, intended use, presentation, proposed claims and mode of action. Compare the therapeutic-product, medical-device and health-supplement possibilities separately; record the reasoning and questions needing clarification. Keep promotional wording provisional through claims substantiation, and assign the unresolved classification in the quality risk register. A useful internal gate is regulatory-owner agreement on the category before committing to a category-specific dossier.
Q.What should a Singapore importer ask an overseas therapeutic-product manufacturer to clarify before accepting its evidence?+
For Singapore therapeutic products, HSA’s registration guidance says overseas drug-product manufacturers may undergo HSA GMP conformity assessment. As an evidence-review practice, ask whether each document concerns the drug substance or finished drug product, which legal entity and manufacturing site it covers, and which operations and products fall within its scope. Request an explanation of document status, issuing organisation and subsequent changes. Review cGMP evidence against the actual supply arrangement, rather than accepting a certificate solely because its title looks relevant.
Q.What belongs in a handover between a product-registration owner and a dealer-licence owner?+
Use an internal handover that connects the product dossier to the proposed import, manufacturing or wholesale operation without treating the owners’ responsibilities as interchangeable. Include product identifiers, dossier version, registration correspondence, manufacturing and supply sites, planned activities, licence-related questions and named decision owners. Identify who communicates changes and who maintains operational records. Connect supply-chain identifiers to lot pedigree and escalation contacts to recall readiness. Close the handover with documented acceptance of responsibilities and a list of unresolved dependencies.
Q.How should a company revisit a device-grouping assessment when its proposed product family changes?+
For Singapore medical devices, HSA’s registration guidance directs applicants to consider grouping criteria. Operationally, reopen the assessment when the proposed family changes rather than copying the previous conclusion. Compare added or removed models, intended uses, design differences, accessories and labelling against the earlier rationale. Use the current instructions for use as a comparison input, not proof of grouping eligibility. Record the reassessment through change control, including the reviewer’s conclusion and any questions to resolve before revising the submission.
Q.What should a company record when considering voluntary notification of a complementary health product?+
For Singapore health supplements, HSA’s health-supplements page links to voluntary notification of complementary health products. As an internal decision record, capture the product identity, classification rationale, formulation and label versions, responsible company, decision owner and reason for proceeding or not proceeding. Keep supporting documents and correspondence linked to that decision. Use contemporaneous recording to preserve what was decided and when. If proceeding, track preparation, submission and subsequent correspondence separately, using status wording that describes the actual event rather than implying approval.
Q.How can foreign authorisations be recorded without assuming a Singapore evaluation route?+
Maintain a foreign-authorisation register as an evidence inventory, not a Singapore route decision. Record the issuing authority, jurisdiction, authorisation type, reference identifier, product and manufacturer covered, document version, conditions and current status. Note differences from the proposed Singapore product, including formulation, intended use, models or manufacturing sites. Preserve source documents with data integrity controls. Separately assign a regulatory reviewer to assess the Singapore pathway and document the basis, including unresolved applicability questions, without letting a foreign-status field populate that conclusion.
Q.What should happen when a submitted file and the current internally approved document no longer match?+
Preserve both versions and establish which file was actually submitted; do not silently replace the submission copy. Compare the differences, identify why they arose and assess their effect on the dossier’s accuracy and associated activities. Use an audit trail to reconstruct the sequence and a deviation record where the mismatch reflects a process failure. The responsible regulatory reviewer can then determine the appropriate external communication, while the internal document owner approves corrections and records the disposition of superseded material.
Q.How can a sales team describe regulatory progress without confusing submission, notification and approval?+
Give sales a controlled status statement tied to a named product, jurisdiction and dated event. Describe the action actually taken and the response actually received; avoid a single cleared-for-market field that collapses different milestones. Have regulatory staff approve external wording and identify what remains unresolved before commercial commitments. Include recurring status errors in management review so ownership and training can be corrected. Keep product status separate from shipment availability and internal release decisions, which answer different operational questions.
Primary sources
Want to see how HSA (Singapore) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
